Navigation Links
Neoprobe Phase 2 Lymphoseek Trial Meets Primary Endpoint

DUBLIN, Ohio--(BUSINESS WIRE)--Jun 20, 2007 - Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced positive preliminary results from a multicenter Phase 2 clinical study of its lead clinical candidate, Lymphoseek(R) (Technetium Tc99m DTPA-mannosyl-dextran). Lymphoseek is a proprietary radioactive targeting agent being developed for use with handheld gamma detection devices, such as Neoprobe's neo2000(R) system, in a surgical procedure known as Sentinel Lymph Node Biopsy (SLNB). The primary endpoint of this multicenter, single-arm, open-label, within-patient, single-dose, multi-stage trial measured the rate at which Lymphoseek localized to lymphoid tissue with a goal of achieving 90% localization. In results reported today, localization of Lymphoseek to lymphoid tissue was observed in over 94% of the SLNB procedures performed as a part of the Phase 2 trial in patients with either breast cancer or melanoma.

This study is being conducted at five of the leading cancer centers in the U.S.: John Wayne Cancer Center; M.D. Anderson, the University of California, San Francisco; University Hospitals - Cleveland (Case Western Reserve); and the University of Louisville. Positive interim results from the trial were announced earlier this year. Neoprobe also reported that no drug-related significant adverse events have been noted in results analyzed to-date. Neoprobe now plans to begin winding down Phase 2 trial activities, collecting the required 30-day patient safety follow-up information and accumulating data to report to FDA. In parallel, Neoprobe is also preparing to submit its Phase 3 pivotal trial protocol to FDA.

About Neoprobe

Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and
'"/>




Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Neoprobe Phase Lymphoseek Trial Meets Primary Endpoint
(Date:8/27/2015)... and TORONTO , Aug. 27, 2015 ... today announced the issuance of a white paper on ... insulin spray product.  The white paper was presented to ... stockholders by Dr. James H. Anderson, Jr. , ... may be viewed online on the Generex website. ...
(Date:8/27/2015)... 2015 Major pharmaceutical and medical device companies and ... in Philadelphia on Oct. 20, discussing ... Hagy of HB Litigation Conferences has announced. ... at http://litigationconferences.com/?p=31886 The program is co-chaired ... Mahoney and Michelle Hart Yeary of Dechert LLP. ...
(Date:8/27/2015)... Aug. 27, 2015  Mytrus, a technology and services company revolutionizing ... electronic informed consent has received approval for use by ... It is the first time e-Consent technology will be ... . Mytrus was also the first ... clinical trial by the U.S. Food and Drug Administration ...
Breaking Medicine Technology:Generex Announces Issuance of Buccal Insulin White Paper 2Generex Announces Issuance of Buccal Insulin White Paper 3Generex Announces Issuance of Buccal Insulin White Paper 4Pharmaceutical, Medical Device Law Seminar Features In-House, Outside Counsel 2Pharmaceutical, Medical Device Law Seminar Features In-House, Outside Counsel 3Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 2Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 3Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 4Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 5Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 6Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 7
... Services is pleased to announce the exciting addition of ... the new Manager of Minerals.  Dr. Al-Ammar brings with ... has over fourteen years of experience with ICP-MS and ... United States and Europe.  Additionally, Dr. Al-Ammar has seven ...
... 15, 2011 PPTA opposes New Jersey Assembly Bill 2003 ... 13 that imposes a new tax on therapies used to ... The Bleeding Disorders Treatment Fund by taxing the manufacturers of ... rebate. PPTA opposes any policy that would impose a tax ...
Cached Medicine Technology:Dr. Assad Al-Ammar Joins Irvine Pharmaceutical Services as the New Minerals Analysis Manager in Response to the Growing Needs for USP Elemental Impurities Testing 2PPTA Opposes Tax on Blood Clotting Factor 2
(Date:8/27/2015)... Del. (PRWEB) , ... August 27, 2015 , ... Dr. ... will be the guest speaker at CURE® magazine’s 3rd Annual MPN Heroes™ recognition ... Dr. Arnold will be among hundreds of attendees honoring eight heroes who have made ...
(Date:8/27/2015)... ... August 27, 2015 , ... Zensah®, ... Glushko, professional Tennis player for Israel in the Women’s Tennis Association (WTA). Glushko ... her training and recovery. , With a focus on technology and comfort, Zensah® ...
(Date:8/27/2015)... ... August 27, 2015 , ... For the first time, Ninja® ... the Nutri Ninja® Auto-iQ Pro Complete and Nutri Ninja Auto-iQ Compact System. These ... drink customization to a whole new level. This line of Nutri Ninja products ...
(Date:8/27/2015)... ... August 27, 2015 , ... Sunbelt® Bakery, maker of ... corn syrup, is changing the expectation of how protein bars should taste with the ... unlike any other protein bar on the market today. , The new Protein ...
(Date:8/27/2015)... ... ... "I need a little help supporting and stabilizing myself when getting into ... "I developed this support handle to give me the extra little boost that I ... a helping hand when stepping into or out of the tub or shower. The ...
Breaking Medicine News(10 mins):Health News:Dr. Jennifer Arnold of ‘The Little Couple’ to Keynote 3rd Annual MPN Heroes™ Recognition Event in Orlando 2Health News:Dr. Jennifer Arnold of ‘The Little Couple’ to Keynote 3rd Annual MPN Heroes™ Recognition Event in Orlando 3Health News:Dr. Jennifer Arnold of ‘The Little Couple’ to Keynote 3rd Annual MPN Heroes™ Recognition Event in Orlando 4Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 2Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 3Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 2Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 3Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 4Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 2Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 3Health News:Inventor and InventHelp Client Develops Bathroom Stabilization Aid (LCC-432) 2
... FRANCISCO, March 26 We are excited ... partner for the,Parkinson,s Disease Foundation. Zoomedia,s initial ... Foundation current website, PDF.org and,the website of ... awareness initiative led by the Parkinson,s Disease ...
... March 27,caregivers at the Motion Picture & Television ... hope of preventing a future strike. More than,570 ... West, were,forced to authorize a strike after management ... the workers, proposals to increase staffing levels and,recruit ...
... global,outsource provider of clinical documentation technology and services, today,announced ... 31, 2007., Financial Highlights-Fourth Quarter of 2007, ... $48.6 million compared,with $51.4 million in the fourth quarter ... the fourth quarter of 2007 from the prior-year,period was ...
... Presbyterian/St. Luke,s,Hospital and Rocky Mountain Pediatric Hematology-Oncology are ... of the Children,s Oncology Group,(C.O.G.). C.O.G. is supported ... world,s largest cooperative childhood, adolescent and young adult,cancer ... States about 9,000 children are diagnosed with,cancer. Because ...
... potential stumbling block, experts say , , WEDNESDAY, March 26 (HealthDay ... help predict future cardiac problems, a new study shows, but ... would be worth the cost. , "It has been shown ... Bild, deputy director of the division of prevention and population ...
... March 26 Michael D. Farley has,joined ... office in Washington,DC as the organization,s Chief ... the Foundation,s overall organizational administration and,field development. ... health organizations, including serving most recently as ...
Cached Medicine News:Health News:Zoomedia Teams Up With The Parkinson's Disease Foundation 2Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 2Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 3Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 4Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 5Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 6Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 7Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 8Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 9Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 10Health News:Spheris Reports Fourth Quarter and Year-End 2007 Results 11Health News:The Rocky Mountain Hospital for Children at Presbyterian/St. Luke's is now Member of the Children's Oncology Group 2Health News:Calcium Scans Help Predict Coronary Risk 2Health News:Michael D. Farley Appointed Chief Operating Officer of Lupus Foundation of America, Inc. 2
Barraquer needle holder, curved, delicate....
Clinical micro clamps by Acland. Matte finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Clinical micro clamps by Acland. Black finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Clinical micro clamps by Acland. Black finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Medicine Products: